about
Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and control of RNA polymerase III-dependent transcription in cancer cellsDEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survivalA comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromesPTEN suppresses the oncogenic function of AIB1 through decreasing its protein stability via mechanism involving Fbw7 alphaProtein kinases and phosphatases in the control of cell fateNext-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategyThe PI3K pathway as drug target in human cancerDual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal CancersNitric oxide-mediated sensitization of resistant tumor cells to apoptosis by chemo-immunotherapeuticsInsulin receptor signaling in normal and insulin-resistant statesAdaptive resistance to targeted therapies in cancerPI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasmsMethodological aspects of the molecular and histological study of prostate cancer: focus on PTENRho kinase proteins--pleiotropic modulators of cell survival and apoptosisRegulation of lipid binding underlies the activation mechanism of class IA PI3-kinasesDiscovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.Maximising the potential of AKT inhibitors as anti-cancer treatmentsInhibition of PI3K prevents the proliferation and differentiation of human lung fibroblasts into myofibroblasts: the role of class I P110 isoformsComputer-aided targeting of the PI3K/Akt/mTOR pathway: toxicity reduction and therapeutic opportunitiesS9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeletonFKBP5 as a selection biomarker for gemcitabine and Akt inhibitors in treatment of pancreatic cancerDiabetes-induced hepatic pathogenic damage, inflammation, oxidative stress, and insulin resistance was exacerbated in zinc deficient mouse modelAlteration of cellular behavior and response to PI3K pathway inhibition by culture in 3D collagen gelsPTEN degradation after ischemic stroke: a double-edged swordRegulation of PTEN stability and activity by Plk3Predicting mTOR inhibitors with a classifier using recursive partitioning and Naïve Bayesian approachesB Cell Receptor Activation Predominantly Regulates AKT-mTORC1/2 Substrates Functionally Related to RNA ProcessingS100B Protein Regulates Astrocyte Shape and Migration via Interaction with Src Kinase: IMPLICATIONS FOR ASTROCYTE DEVELOPMENT, ACTIVATION, AND TUMOR GROWTHInositol polyphosphate 4-phosphatase B as a regulator of bone mass in mice and humansDirect positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase.Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancerDeubiquitinases Modulate Platelet Proteome Ubiquitination, Aggregation, and Thrombosis.TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.miR-17-92 cluster targets phosphatase and tensin homology and Ikaros Family Zinc Finger 4 to promote TH17-mediated inflammationBoth decreased and increased SRPK1 levels promote cancer by interfering with PHLPP-mediated dephosphorylation of Akt.Plk1 protein phosphorylates phosphatase and tensin homolog (PTEN) and regulates its mitotic activity during the cell cycleA novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate.Casein kinase 2 dependent phosphorylation of neprilysin regulates receptor tyrosine kinase signaling to AktFormal Modeling of mTOR Associated Biological Regulatory Network Reveals Novel Therapeutic Strategy for the Treatment of Cancer.
P2860
Q24303535-C0417DBC-0E42-4426-BE6B-E1B0615FDEB9Q24311448-E36FE934-C343-45F0-AC0E-E90A685B89BFQ24320313-107B0F02-2037-40DF-B4A4-695408A66A49Q24337070-FF7D92DE-434A-4F8D-90AD-9FF3803BD4F7Q24604987-FFF4C828-6274-4486-8514-ED2C88AD1A89Q24628724-A1A3794B-D101-4DFD-8181-556C01ACF702Q24632283-BABFF9D5-15B9-4F15-B75E-370AF067238BQ26781362-F94AA658-AA0A-4277-8D4D-C273C62710EBQ26782525-EB9181FA-BC27-4B3F-9066-17C33290F282Q26823171-EF6DA9E5-E530-4A1B-AEC3-1A94B5BF67C5Q26849316-831410E4-006C-409E-B3F5-7089192909CBQ26862544-DC338BDB-4503-4BD3-92E8-EC9F0A9C5554Q27005677-C20FA823-FF23-45B3-B888-E03C554D2ACBQ27023537-85EE8549-47AA-4C11-AC4E-ECF04968A721Q27675831-71212511-E345-4F8A-A6A0-E40D5315D424Q27711042-55136A11-D0FD-4410-9953-29E056B10825Q27852994-5763B3F5-D37F-4A41-B8EF-44397BBB1BE5Q28072254-B661DA0B-2D27-46D0-980A-28B6039CA453Q28392359-E34F4800-8218-4FD9-A3A9-D849FC85D193Q28397537-D95FBE79-6510-4A5C-8CD9-18945E29895DQ28475032-3B066B28-FB1E-4093-8CC3-CB650AA235B9Q28483623-B91C8AFC-2CA9-4C47-87FB-2AD0DEA20E1AQ28484324-2F9F9EC2-BAE3-4E00-BDA1-2FC158446847Q28484532-6269C666-8D08-4822-B270-17D018626B98Q28512531-1ED13E6C-A7BA-45B9-B8A3-C91C94FC03A5Q28512686-BDBEFDF6-AAE0-43B0-9853-0C94B82C312EQ28538732-3BE9F65D-2C3A-4E24-A764-4DE97E4FD024Q28553375-23B620C6-1F11-4F74-9F4E-4F2986EA9187Q28566413-A5A91827-10DF-4A2B-9909-410D2FB62435Q28586887-93736062-A8F0-4BB7-BD2D-7C7833B8E177Q30156937-4C354A50-4866-4A18-BA91-92D4F285A2A4Q30425261-1BBEF4A7-319C-42D5-864A-0EC74D469790Q30683490-41B8FD42-3008-489A-B705-0BA0B454E6D6Q33442621-F1FE0855-6853-4BBA-9232-089F23BEEABFQ33556109-DF30B6A1-2FE4-465D-846E-92360C8F5355Q33605329-F8C06CA8-6F6C-47F2-BFE4-DE20CC072C43Q33619449-4924AF30-38B7-42C8-BEBE-A24144FF76D5Q33620076-A7878E14-E373-4D6C-B4B0-290511F0919AQ33721897-A35EB7E1-B259-463D-B963-9F73B490E7AEQ33790320-64E8642B-C3DF-4C45-811B-375A0217913A
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
The PTEN-PI3K pathway: of feedbacks and cross-talks.
@ast
The PTEN-PI3K pathway: of feedbacks and cross-talks.
@en
The PTEN-PI3K pathway: of feedbacks and cross-talks.
@nl
type
label
The PTEN-PI3K pathway: of feedbacks and cross-talks.
@ast
The PTEN-PI3K pathway: of feedbacks and cross-talks.
@en
The PTEN-PI3K pathway: of feedbacks and cross-talks.
@nl
prefLabel
The PTEN-PI3K pathway: of feedbacks and cross-talks.
@ast
The PTEN-PI3K pathway: of feedbacks and cross-talks.
@en
The PTEN-PI3K pathway: of feedbacks and cross-talks.
@nl
P356
P1433
P1476
The PTEN-PI3K pathway: of feedbacks and cross-talks.
@en
P2093
A Carracedo
P P Pandolfi
P2888
P304
P356
10.1038/ONC.2008.247
P407
P577
2008-09-01T00:00:00Z
P5875
P6179
1040854906